If approved, the pill is expected to be far easier to administer than current injectables — and far easier to manufacture.

The major U.S. equities indexes were mixed at midday Thursday, with the Dow Jones Industrial Average down close to 400 points ...

Wall Street stocks ended mixed on Thursday, lifted by Eli Lilly and Apple, as investors weighed progress in U.S. trade ...

Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...

The S&P 500 ended higher on Thursday, lifted by Eli Lilly and Apple, as investors weighed progress in U.S. trade negotiations ...

The UnitedHealth slide weighed heavily on the Dow, which fell 500 points, or 1.3%, Thursday morning.

Lilly said its investigational once-daily pill achieved positive topline results in a late-stage study evaluating the safety and efficacy of orforglipron compared with a placebo in adults with type 2 ...

The stock's fall snapped a three-day winning streak.

Eli Lilly and Company (LLY) is currently at $852.76, up $117.87 or 16.04% --Would be highest close since March 24, 2025, when it closed at $864.90 --On pace for largest percent increase since June 29, ...

U.S. stocks are holding steadier in the final day of trading for their holiday-shortened week. The S&P 500 rose 0.2% Thursday ...

Most U.S. stocks rose, but the worst drop for UnitedHealth Group in a quarter century kept Wall Street in check.

U.S. stocks saw mixed movements as UnitedHealth plunged 22% after a weak earnings report, dragging the Dow down 527 points.